Kite nabs engineered allogeneic T-cell tech from UCLA

Blue stem cells

Kite Pharma ($KITE) has always been focused on engineering a patient’s own T cells to treat their cancer. But now, it’s in-licensed tech to create off-the-shelf T-cell therapies from renewable donor pluripotent stem cells.

The agreement is an exclusive worldwide license with the University of California at Los Angeles (UCLA). The technology is intended to replicate the human thymic environment to support the ex vivo differentiation of T cells from primary and reprogrammed pluripotent stem cells.

The in-licensed ATO system is expected to make the production of T cells sustainable and scalable by using pluripotent stem cell lines; it offers a platform to enable additional gene-engineering to develop these off-the-shelf allogeneic T-cell therapies.

Whitepaper Download

Reducing the Complexity and Costs of Channel Planning and Logistics

How can you make the process of bringing your product to market less complex while also reducing costs? This Whitepaper identifies opportunities to simplify channel strategies for biopharma companies, their customers and patients. Discover how you can deliver savings and innovation to your business.

Kite was previously focused on an autologous approach, which uses the patient’s own stem cells, rather than an allogeneic one based on the use of donor stem cells.

"This ATO system represents a significant breakthrough in stem cell biology that will drive our long-term strategy to develop best-in-class allogeneic T-cell therapies," said Kite VP of R&D and CMO Dr. David Chang in a statement.

He continued, "This platform provides a renewable source of T-cells and can be further exploited with gene engineering, including chimeric antigen receptors, T-cell receptors and other gene modifications of interest, to generate potent T-cell products that have the potential to be resistant to rejection and to bear no risk of graft-versus-host disease."

Low output of T cells and donor-to-donor variability have previously limited the engineering or commercial-scale manufacturing of T cells. But the ATO system is expected to improve upon that.

Under the deal, Kite gets exclusive use of the technology to develop T-cell products in oncology. The Santa Monica, CA-based company also agreed to support ongoing preclinical research by Dr. Crooks to continue to improve the ATO platform.

Kite had $575 million in cash at the end of the first quarter with a net loss of $43.9 million during that period.

- here is the release

Related Articles:
Rock star researcher licenses out new CAR-T platform to upstart
Kite dives into manufacturing amid CAR-T frenzy
NIH clamps down on two labs, interrupting trial work by Kite’s star scientist
ASCO data advance Juno, Kite toward targeted 2017 CAR-T approvals

Suggested Articles

The money will support work on a biologic drug cocktail that Lumen thinks can be a scalable, inexpensive fix for gastrointestinal symptoms.

The readouts link the oral oxidative phosphorylation blocker imeglimin to near- and long-term improvements when given as a monotherapy and in combos.

Scientists at the University of Toronto, in collaboration with Agios, identified 182 genes that allow cancer cells to evade the immune system.